TLDR:
- Baltimore-based Infinity Bio, an antibody profiling company, raised $4.5 million in a funding round led by PTX Capital and Blackbird BioVentures.
- Founded by Larman and Elledge, Infinity Bio focuses on antibody profiling using MIPSA technology to discover disease mechanisms and immune responses.
Baltimore-based Infinity Bio, founded by H. Benjamin Larman and Steve Elledge, raised $4.5 million in a funding round led by PTX Capital and Blackbird BioVentures. The company, established last year, specializes in antibody profiling using cutting-edge technology known as Molecular Indexing of Proteins by Self-Assembly (MIPSA). This technology allows Infinity Bio to map antibody reactivity at scale across viral antigens, self-antigens, and allergens, enabling the discovery of disease mechanisms, vaccine development, and identification of immune responses, especially for various cancers.
Infinity Bio’s CEO, Joy Nassif, a management veteran in healthcare firms, leads the company since June 2023. The company’s board includes Caroline Popper, an internist and pathologist associated with the John Hopkins Bloomberg School of Public Health. PTX Capital and Blackbird BioVentures’ investments in Infinity Bio reflect the potential for robust and comprehensive antibody profiling to unlock insights across important human diseases, as highlighted by Gregor Mendel Professor of Genetics at Harvard University, Steve Elledge.
PTX Capital, with six investments since its founding in 2021, has a recent portfolio that includes Pair Team, Scene Health, Delfi Diagnostics, and ArrePath. Blackbird BioVentures’ portfolio lists Modra, ProFlowers, AlloCrypt, and Talapa Bio among its investees.
